GCGR Recombinant Monoclonal Antibody

Code: CSB-RA009316MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Rat

Application: ELISA

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P47871

Target Names

GCGR

Alternative Names

Glucagon receptor (GL-R) , GCGR

Species Reactivity

Rat

Immunogen

Recombinant Human GCGR protein

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

7G3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol

Recommended Dilution

Application	Recommended Dilution
ELISA	1:5000-1:50000

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Rat Gcgr with Anti-Gcgr Recombinant Antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized Rat Gcgr (CSB-MP009316RA1) at 2 μg/mL can bind Anti-Gcgr recombinant antibody. The EC₅₀ is 29.63-35.34 ng/mL.

Description

The glucagon receptor (GCGR) serves as a critical G protein-coupled receptor that mediates glucagon's effects on glucose homeostasis, primarily in the liver where it stimulates glycogenolysis and gluconeogenesis. This receptor has become an increasingly important target in metabolic disease research, particularly in studies exploring therapeutic strategies for type 2 diabetes and obesity, where modulating glucagon signaling may offer novel treatment approaches.

This recombinant monoclonal antibody against GCGR, clone 7G3, offers researchers the advantages inherent to recombinant technology. Because the antibody sequence is defined and produced through controlled expression systems, you can expect consistent performance across different lots, eliminating the variability that can complicate long-term studies or multi-site collaborations. The antibody has been affinity-purified to ensure high specificity for your target.

Functional validation demonstrates robust binding activity against rat GCGR. In ELISA-based binding assays using immobilized rat GCGR at 2 μg/mL, this antibody achieved an EC50 of 29.63–35.34 ng/mL, indicating strong affinity suitable for sensitive detection applications. For ELISA workflows, recommended working dilutions range from 1:5000 to 1:50000, providing flexibility to optimize signal-to-background ratios for your specific experimental conditions.

Supplied in a liquid format containing 50% glycerol and PBS at pH 7.4 with Proclin 300 as preservative, this antibody is ready for immediate use in your assays. The human IgG1 isotype format may also prove useful for researchers requiring specific Fc-mediated properties in their experimental design. This antibody supports investigations into glucagon signaling pathways, metabolic regulation, and receptor biology in rat model systems.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.

Gene References into Functions

3.0 A-resolution crystal structure of the full-length human glucagon receptor (GCGR) in complex with a glucagon analogue and partial agonist, NNC1702 PMID:29300013
work toward the mapping of interactions between the polypeptide hormone glucagon and the glucagon receptor PMID:28508109
3.0 A crystal structure of full-length GCGR containing both the extracellular domain and transmembrane domain in an inactive conformation PMID:28514451
This work suggests that RAMP2 may modify the agonist activity and trafficking of the GCGR, with potential relevance to production of new peptide analogs with selective agonist activities. PMID:28586439
Data suggest that GCGR activation proceeds via a mechanism in which transmembrane helix 6 (TM6) is held in an inactive conformation by a conserved polar core and a hydrophobic lock (involving intracellular loop 3, IC3); mutations in the corresponding polar core of GCGR disrupt these inhibitory elements, allow TM6 to swing outward, and induce constitutive G protein signaling. PMID:28356352
The activation of the GCGR is characterized by the outward movement of the intracellular side of helix VI. In the active state of the GCGR, the Arg173(2.46)-Ser350(6.41) and Glu245(3.50)-Thr351(6.42) hydrogen bonds break, and the chi1 rotamer of Phe322(5.54) changes from perpendicular to parallel to helix VI. PMID:27094704
In the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), the extracellular domain is required for signaling even when the hormone is covalently linked to the transmembrane domain. PMID:27226600
2.5 A crystal structure of human GCGR in complex with the antagonist MK-0893, which is found to bind to an allosteric site outside the seven transmembrane helical bundle in a position between TM6 and TM7 extending into the lipid bilayer PMID:27111510
Molecular dynamics and disulfide crosslinking studies suggest that apo-GCGR can adopt both an open and closed conformation associated with extensive contacts between the ECD and 7TM domain. Glucagon binds to GCGR by a conformational selection mechanism. PMID:26227798
glucagon cell adenomatosis with GCGR germline mutations seems to follow an autosomal-recessive trait. PMID:25695890
Using a real-time time-resolved FRET-based internalization assay, we show that GLP-1R, GIPR, and GCGR internalize with differential properties PMID:25451942
crystal structure of the seven transmembrane helical domain of human GCGR at 3.4 A resolution, and a hybrid model of glucagon bound to GCGR to understand the molecular recognition of the receptor for its native ligand PMID:23863937
Letter/Case Report: nonfunctional glucagon cell adenomatosis with no detectable glucagon receptor mutations. PMID:23407487
GRA1 is a potent glucagon receptor antagonist with strong antihyperglycemic efficacy in preclinical models and prominent effects on hepatic gene-expression related to amino acid metabolism PMID:23185367
F22, V23, M27, and D15 of GCGR are the most important residues for glucagon binding. PMID:22893257
in addition to activation of the classic cAMP/protein kinase A (PKA) pathway, activation of GCGR also induced beta-catenin stabilization and activated beta-catenin-mediated transcription PMID:22438981
analysis of glucagon receptor antagonists with reduced molecular weight and lipophilicity PMID:22119466
The P86S mutant GCGR shows abnormal receptor internalization & calcium mobilization, & causes apoptosis. It cases Mahvash disease (hyperglucagonemia, hypoglycemia, pancreatic neuroendocrine tumors). PMID:21680267
substituted cysteine accessibility method and 3D-molecular modeling to study the N-terminal domain; results showed that Asp(63), Arg(116), and Lys(98) are essential for the receptor structure and/or ligand binding PMID:20647307
The [Ca2+] response is induced by glucagon mainly via the coupling of GCGR to the Galphaq/11 and Galphai/o proteins. PMID:19903011
The Gly40Ser polymorphism of the GCGR gene is associated with higher risk of hypertension and with enhanced proximal tubular sodium reabsorption. PMID:11692154
Gly40Ser mutation in the glucagon receptor gene is not associated with type 2 diabetes in a Brazilian population, but a reduction of insulin secretion was observed in Gly40Ser carriers. PMID:11961492
Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus PMID:12724331
Expression of peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha), known to be upregulated in the liver by fasting, was found to abolish the cAMP-dependent downregulation of glucagon receptor mRNA expression in vitro. PMID:17374560